山东东方海洋科技股份有限公司 山东东方海洋科技股份有限公司 关于营业收入扣除情况及扣除后的营业收入金额的说明 山东东方海洋科技股份有限公司（以下简称"公司"）2024 年 12 月 31 日的合并及 公司资产负债表，2024 年度的合并及公司利润表、合并及公司现金流量表、合并及公 司股东权益变动表以及财务报表附注经和信会计师事务所（特殊普通合伙）审计，并出 具了"和信审字（2025）第 000608 号"标准无保留意见审计报告。按照《深圳证券交易 所股票上市规则》以及《深圳证券交易所上市公司自律监管指南第 1 号——业务办理》 的有关规定，现将本公司 2024 年度营业收入扣除情况及扣除后的营业收入金额说明如 下： 一、公司经审计的扣除非经常性损益前后的净利润 单位：人民币万元 | 项目 | 2024 年度 | 2023 年度 | | --- | --- | --- | | 归属于上市公司股东的净利润 | -19,037.91 | 174,960.02 | | 归属于上市公司股东的扣除非经常性损益的净利润 | -19,961.13 | -63,588.76 | 二、营业收入扣除情况表 单位：人民币万元 | 项 ...

山东东方海洋科技股份有限公司 2024 年度内部控制自我评价报告 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现公司发展战略。由于内部控 制存在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的 变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据 内部控制评价结果推测未来内部控制的有效性具有一定的风险。 二、内部控制评价结论 根据报告期内公司财务报告内部控制重大缺陷的认定情况，于内部控制评价 报告基准日，不存在财务报告内部控制重大缺陷，董事会认为，公司已按照企业 内部控制规范体系和相关规定的要求在所有重大方面保持了有效的财务报告内 部控制。 根据公司非财务报告内部控制重大缺陷认定情况，于内部控制评价报告基准 日，公司未发现非财务报告内部控制重大缺陷。 自内部控制评价报告基准日至内部控制评价报告发出日之间未发生影响内 部控制有效性评价结论的因素。 1 三、内部控制评价工作情况 （一）内部控制评价范围 公司按照风险导向原则确定纳入评价范围的主要单位、业务和事项以及高风 险领域。 根据《企业内部控制基本规范》及其配 ...

山东东方海洋科技股份有限公司 监事会 二〇二五年四月二十八日 1 山东东方海洋科技股份有限公司 监事会对公司内部控制评价报告的意见 根据《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》《深圳证券交易所上市公司自律监管指南第 1 号——业务办理》《内部控 制制度》等有关规定，监事会对公司《2024 年度内部控制评价报告》进行了审 核，现发表意见如下： 公司已根据中国证监会、深圳证券交易所的要求，遵循内部控制的基本原则， 结合自身实际情况，不断完善公司内部控制制度，保证了公司业务活动的正常进 行，保护了公司财产的安全和完整。公司内部控制组织结构完整，内部审计部门 及人员配备齐全，公司对内部控制重点活动的执行及监督充分有效。因此，监事 会对公司 2024 年度内部控制情况表示认可，公司《2024 年度内部控制评价报告》 全面、真实、准确、客观地反映了公司内部控制实际情况。 ...

一、审议通过《公司 2024 年度监事会工作报告》 山东东方海洋科技股份有限公司 第八届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山东东方海洋科技股份有限公司（以下简称"公司"）第八届监事会第十一次会 议于 2025 年 4 月 21 日以电话、邮件等形式通知全体监事，会议定于 2025 年 4 月 25 日上午以通讯方式召开，会议应到监事 5 人，实际参加及审议监事 5 人，会议 由监事会主席王顺奎先生召集并主持。本次会议的召集、召开符合《公司法》和 《公司章程》的有关规定。会议以通讯表决方式审议并通过如下决议： 证券代码：002086 证券简称：东方海洋 公告编号：2025-023 监事会认为：2024 年监事会严格按照《公司章程》及《监事会议事规则》的 规定召开监事会，公司监事能够认真履行职责，通过列席董事会、股东大会和对 下属企业的检查，对公司经营、财务运作以及董事会和经营班子履行职责的合法 合规性进行监督。报告期内，未发现公司存在违法违规行为。 表决结果：5 票同意，0 票反对，0 票弃权。 该工作报告需提交公司年度 ...

证券代码：002086 证券简称：东方海洋 公告编号：2025-022 山东东方海洋科技股份有限公司 第八届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 山东东方海洋科技股份有限公司（以下简称"公司"）第八届董事会第二十次会 议于 2025 年 4 月 21 日以电话、邮件等形式通知全体董事，会议定于 2025 年 4 月 25 日以通讯方式召开，应参加董事 9 人，实际参加审议表决董事 9 人。会议的召集、 召开符合《公司法》和《公司章程》规定，会议由董事长张乐先生召集并主持。会 议以通讯表决方式通过以下议案： 一、审议通过《公司 2024 年度董事会工作报告》 董事会工作报告全面、真实、完整地反映了公司本年度董事会工作情况。具体 内容详见公司《2024 年年度报告》第三节管理层讨论与分析相关章节。 鉴于公司 2024 年度可供股东分配的利润为负，结合公司实际经营发展情况， 公司 2025 年度日常经营对资金的需求较大，为保障公司正常生产经营和稳定发展 需要，更好地维护全体股东的长远利益，建议 2024 年度不派发现金红利，不送 ...

证券代码：002086 证券简称：东方海洋 公告编号：2025-016 山东东方海洋科技股份有限公司 关于公司 2024 年度拟不进行利润分配的专项说明 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 山东东方海洋科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召 开了第八届董事会第二十次会议、第八届监事会第十一次会议，审议通过了《公 司 2024 年度利润分配预案》。公司董事会、监事会均认为本次利润分配预案符 合《公司法》等法律法规及《公司章程》关于利润分配的相关规定，综合考虑了 公司实际经营情况、未来业务发展及资金需求。本议案尚需提交公司 2024 年度 股东大会审议，现将具体情况公告如下： 为保障公司正常生产经营和未来发展，公司拟定 2024 年度利润分配方案为： 公司 2024 年度拟不派发现金红利，不送红股且不进行资本公积金转增股本。 二、最近三个会计年度现金分红情况 | 项目 | 年度 2024 | 年度 2023 | 年度 2022 | | --- | --- | --- | --- | | 现金分红总额（元） | 0 | ...

Revenue and Profitability - The company's revenue for Q1 2025 was ¥75,273,204.39, representing a 12.95% increase compared to ¥66,643,850.46 in the same period last year[5] - The net profit attributable to shareholders was -¥22,099,956.99, a decline of 53.58% from -¥14,389,779.83 year-over-year[5] - The operating profit was -¥22,659,510.40, worsening from -¥14,465,916.86 in the previous period, representing an increase in losses of approximately 56.5%[16] - The net profit attributable to the parent company was -¥22,099,956.99, compared to -¥14,389,779.83 in the previous period, reflecting a decline of approximately 53.5%[16] - The total comprehensive income attributable to the parent company was -¥22,111,834.94, compared to -¥14,304,961.49 in the previous period, indicating a decrease of about 54.1%[17] Cash Flow and Liquidity - The net cash flow from operating activities was -¥54,695,225.37, which is a 19.16% decrease compared to -¥45,898,806.38 in the previous year[5] - Cash flow from operating activities showed a net outflow of -¥54,695,225.37, compared to -¥45,898,806.38 in the previous period, indicating a deterioration in cash flow by about 18.9%[18] - The company received cash from operating activities totaling ¥95,209,947.20, an increase from ¥73,953,579.28 in the previous period, reflecting a growth of about 28.5%[17] - Cash and cash equivalents decreased to ¥312,254,508.42 from ¥404,608,292.25, a decline of about 22.8%[12] - Cash and cash equivalents at the end of the period were ¥87,910,344.68, down from ¥358,430,352.03 at the end of the previous period, a decrease of approximately 75.5%[18] - The net cash flow from financing activities was ¥991,320.00, a significant decrease from ¥269,858,986.67 in the previous period, indicating a decline of approximately 99.6%[18] - The company incurred a total operating cash outflow of ¥149,905,172.57, compared to ¥119,852,385.66 in the previous period, representing an increase of about 25.1%[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,735,204,240.75, down 4.76% from ¥1,821,861,787.75 at the end of the previous year[5] - Current liabilities decreased to ¥150,757,002.02 from ¥213,645,371.09, a reduction of approximately 29.4%[13] - Non-current liabilities decreased to ¥163,643,461.87 from ¥166,347,902.63, a decrease of approximately 1.6%[13] - The equity attributable to shareholders decreased by 1.54% to ¥1,409,414,538.22 from ¥1,431,526,373.16 at the end of the previous year[5] Operational Performance - Total operating revenue for the current period reached ¥75,273,204.39, an increase from ¥66,643,850.46 in the previous period, representing a growth of approximately 9.8%[15] - Total operating costs increased to ¥100,826,802.20 from ¥83,618,008.07, reflecting a rise of about 20.5%[15] - The cost of goods sold rose significantly to ¥65,682,585.84 from ¥50,025,307.02, indicating an increase of approximately 31.3%[15] - The company's subsidiary, Avioq, Inc., experienced a significant decline in sales of HTLV test kits, impacting net profit and net profit excluding non-recurring gains and losses[8] Shareholder Information - The total number of common shareholders at the end of the reporting period was 101,588[10] - The basic and diluted earnings per share remained at -¥0.01, unchanged from the previous year[5] - The weighted average return on equity was -1.56%, a decrease of 0.67% compared to -0.89% in the same period last year[5] - The company reported non-recurring gains of ¥2,584,979.85, primarily from government subsidies and other income[7] - The company reported a tax expense of ¥15,531.36, compared to ¥10,203.33 in the previous period, reflecting an increase of approximately 52.8%[16]

Financial Performance - The company's operating revenue for 2024 was ¥340,159,362.15, a decrease of 22.20% compared to ¥437,233,445.62 in 2023[22] - The net profit attributable to shareholders for 2024 was -¥190,379,059.47, representing a decline of 110.88% from ¥1,749,600,271.35 in 2023[22] - The net cash flow from operating activities was -¥193,108,739.30, a significant drop of 318.07% compared to -¥46,190,507.48 in 2023[22] - The total assets at the end of 2024 were ¥1,821,861,787.75, down 32.71% from ¥2,707,578,833.26 at the end of 2023[22] - The net assets attributable to shareholders decreased by 11.49% to ¥1,431,526,373.16 from ¥1,617,399,975.20 in 2023[22] - The basic earnings per share for 2024 was -¥0.10, a decline of 111.24% from ¥0.89 in 2023[22] - The company reported a weighted average return on equity of -12.49% for 2024[22] - The net profit after deducting non-recurring gains and losses was -¥199,611,273.52, an improvement of 68.61% from -¥635,887,563.83 in 2023[22] - The overall financial performance indicates a challenging environment, with significant losses and a need for strategic adjustments to improve profitability[26] Revenue Breakdown - Revenue from the aquaculture segment was ¥74,444,071.28, down 15.50% from ¥88,096,305.46 in the previous year, accounting for 21.89% of total revenue[60] - Revenue from the seafood processing segment increased by 23.73% to ¥159,957,468.48, representing 47.02% of total revenue[60] - Revenue from in vitro diagnostics plummeted by 58.30% to ¥81,217,453.55, making up 23.88% of total revenue[60] - The company achieved a gross margin of 30.87% in the in vitro diagnostics segment, down 28.88% year-over-year[62] - The company’s revenue from domestic trade rose by 50.29% to ¥72,594,721.93, with a gross margin of 12.54%[62] Market and Industry Focus - The company is focusing on the development of marine and health industries, aiming for sustainable growth through technological innovation and industry transformation[36] - The marine aquaculture industry is transitioning towards modern, eco-friendly practices, with a focus on high-quality, standardized production methods[31] - The health industry is experiencing a digital transformation, improving service quality and efficiency through AI and other technologies[35] - The company is committed to expanding its market presence and enhancing its competitive edge in both domestic and international markets[31] - The company is actively expanding its market presence both domestically and internationally, aiming to enhance brand recognition and core competitiveness[41] Research and Development - The company has established 7 national R&D platforms and 11 provincial R&D platforms, strengthening its technological innovation capabilities[50] - The company’s R&D team includes over 70 professionals in the field of biomedicine and in vitro diagnostics, with a focus on innovative technology development[58] - The company is developing a non-invasive test kit for detecting Helicobacter pylori, which is currently in the clinical trial phase[71] - The company is focusing on expanding its product line in vitamin testing, with new assays for both water-soluble and fat-soluble vitamins expected to improve clinical nutritional assessments[73] - The ongoing R&D efforts are expected to strengthen the company's position in the immunodiagnostic field and enhance its brand influence[72] Governance and Management - The company maintains a complete corporate governance structure with independent operation capabilities in finance, procurement, production, and sales[137] - The company has appointed a new financial director effective from June 28, 2024[140] - The company is focused on maintaining independent operations and governance amidst its diverse shareholder base[137] - The company has established specialized committees within its board to enhance governance and decision-making[137] - The company is undergoing a significant management restructuring, with several key positions being filled and replaced as part of the transition[143] Environmental and Social Responsibility - The company adheres to multiple environmental protection laws and standards, ensuring compliance with national and local regulations[177] - The company has implemented advanced environmental management practices to prevent pollution and promote energy conservation[180] - The company actively participates in social responsibility initiatives, contributing to community development and promoting a harmonious corporate culture[183] - The company has conducted regular safety training and inspections to ensure compliance with safety regulations and prevent accidents[183] - The company has established an ISO14001 environmental management system to enhance its environmental management capabilities and competitiveness[181] Challenges and Risks - The company has faced regulatory penalties for non-operational fund occupation and inaccurate performance forecasts[153] - The company acknowledges the challenges posed by environmental factors and resource competition in the marine aquaculture sector[97] - The company faces risks related to disease outbreaks in aquaculture, with potential annual economic losses exceeding 10 billion RMB if not managed properly[118] - The company faces risks in the export processing business due to international economic uncertainties and rising labor costs, impacting market conditions negatively[123] - The company has reported a significant discrepancy between the 2021 performance forecast and the actual audited net profit, leading to a public reprimand[153] Future Outlook - The company is optimistic about the future of the health industry, viewing it as a new growth point for the national economy[105] - The company aims to accelerate the development of in vitro diagnostics and precision medicine, leveraging existing research technology, talent, and quality control systems[106] - The company plans to enhance its market competitiveness by emphasizing standardized, high-precision, and market-oriented processing in its fisheries business[106] - The company aims to provide standardized and cost-effective solutions for thrombotic risk assessment and monitoring of thrombolytic therapy[72] - The company plans to enhance its domestic marketing efforts and expand international sales channels to capture market share[117]

山东东方海洋科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 1. 艾维可生物科技有限公司今年对公司的业绩影响较小，本次获批上市的 D-二聚体（D-Dimer）测定试剂盒（磁微粒化学发光法）、骨钙素（0C）测定试 剂盒（磁微粒化学发光法）、维生素 B12（VB12）测定试剂盒（磁微粒化学发 光法）、纤维蛋白原降解产物（FDP）测定试剂盒（磁微粒化学发光法）的投产 及对公司业绩的后续影响具有不确定性，请广大投资者注意投资风险。 证券代码：002086 证券简称：东方海洋 公告编号：2025-014 2. 本次产品获证后还未投入生产，其实际销售情况受市场拓展力度及市场 实际需求等多重因素影响，目前尚无法预测上述获批产品对公司未来业绩的具体 影响，请广大投资者注意投资风险。 请广大投资者充分阅读本公告正文表述的相关风险事项，公司特别提示投资 者理性投资。 山东东方海洋科技股份有限公司（以下简称"公司"）全资子公司艾维可生物 科技有限公司自主研发的 D-二聚体（D-Dimer）测定试剂盒（磁微粒化学 ...

证券代码：002086 证券简称：东方海洋 公告编号：2025-013 山东东方海洋科技股份有限公司 诉讼及诉讼进展公告 本公司及董事会全体成员保证信息披露的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示 1．案件所处的诉讼阶段：①第三人撤销之诉案件：山东省人民检察院已受理；② 第一批投资者诉讼案件：其中新增5名原告已达成诉前调解并经法院确认，另公司对4 名一审原告提出上诉，二审诉讼开庭，尚未作出终审判决/裁定；③第二批投资者诉讼 案件：233名原告法院已结案；33名原告在诉前调解阶段撤诉；57名原告法院已立案， 尚未开庭审理；④普通破产债权确认纠纷案件：法院已立案，尚未开庭审理。 2．上市公司所处的当事人地位：被告；第一批投资者诉讼二审案件为上诉人(一审 被告)。 3．涉案的金额：①第三人撤销之诉案件：撤销支付本金3,000万元、逾期使用费(以 3,000万元为基数，按照年利率24%自2018年9月17日起计算至实际给付之日，并扣除山 东东方海洋集团公司已经完成支付的6万元)、律师费20,000元、保险费135,450元，与其 他被告共同承担案件受理费192,577元。②第一批投资者诉讼 ...